Clinical trials: Transformed Small Cell Lung Cancer
Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC )
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well PF-08634404 works when given alone or with chemotherapy .
- Conditions
- Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms
- Trial name
- NCT07476287
- Testing
- PF-08634404, Chemotherapy
- Where
- 61 sites in United States, Australia and 10 more
- Volunteers
- 40 people
- Sponsor
- Pfizer
Neoplasms
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in patients with solid tumors and aggressive…
- Trial name
- NCT02635672
- Testing
- VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda
- Where
- 16 sites in United States, Chile and 1 more
- Volunteers
- 110 people
- Sponsor
- Vincerx Pharma, Inc.
Small Cell Lung Cancer, Non Small Cell Lung Cancer
Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression
This single-center, prospective study and aims to evaluate the efficacy and safety of limertinib combined with etoposide and carboplatin in EGFR-mutant NSCLC patients who develop small-cell lung cancer transformation following…
- Conditions
- Small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer NSCLC
- Trial name
- NCT07001995
- Testing
- limertinib, etoposide and carboplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hunan Province Tumor Hospital
Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer
Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
This open-label, Phase I/II trial is studying the safety and effectiveness of an experimental drug combination, lurbinectedin with osimertinib, against a rare type of cancer known as transformed small cell lung cancer (SCLC).
- Trial name
- LOTS (NCT07153055)
- Testing
- Lurbinectedin, Osimertinib
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Misty Shields
Cancer
Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation
RATIONALE: Antivirals such as ribavirin are used to treat infections caused by viruses. It is not yet known if ribavirin is more effective with or without monoclonal antibody therapy in treating patients who develop RSV pneumonia…
- Trial name
- NCT00014391
- Testing
- palivizumab, ribavirin
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Small Cell Lung Cancer
Transformation Into Small Cell Lung Cancer : a Mode of Resistance to Treatment
The discovery of oncogenic mutations and the use of targeted therapies have transformed the management of certain tumors. Thus 12 to 15% of bronchial adenocarcinomas (AD) carry mutations of EGFR and receive from the first line…
- Trial name
- TransCPC (NCT03419286)
- Volunteers
- 62 people
- Sponsor
- University Hospital, Grenoble
Solid Tumor, Non-Small Cell Lung Cancer Recurrent
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma
The main purpose of this study is to evaluate the safety, tolerability, and efficacy of the study drug known as galunisertib in combination with nivolumab in participants with advanced refractory solid tumors and in recurrent or…
- Conditions
- Solid Tumor, Non-Small Cell Lung Cancer Recurrent, Hepatocellular Carcinoma Recurrent
- Trial name
- NCT02423343
- Testing
- Galunisertib, Nivolumab
- Where
- 9 sites in United States, Spain
- Volunteers
- 41 people
- Sponsor
- Eli Lilly and Company
Ovarian Cancer, Epithelial, Gastric Cancer
A Study of NX-1607 in Adults With Advanced Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
- Conditions
- Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05107674
- Testing
- NX-1607, Paclitaxel
- Where
- 17 sites in United States, United Kingdom
- Volunteers
- 345 people
- Sponsor
- Nurix Therapeutics, Inc.
Bladder Cancer, Breast Cancer
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer
- Trial name
- NCT00004065
- Testing
- tanespimycin
- Where
- 2 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Chronic Myeloproliferative Disorders
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Motexafin gadolinium may increase the effectiveness of doxorubicin by making tumor cells more sensitive to…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT00036790
- Testing
- doxorubicin hydrochloride, motexafin gadolinium
- Where
- 2 sites in United States
- Sponsor
- University of Wisconsin, Madison
Cancer
Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation
RATIONALE: Captopril may protect the lungs from the side effects of bone marrow or stem cell transplantation. PURPOSE: Randomized phase III trial to determine the effectiveness of captopril to lessen the side effects in patients…
- Trial name
- NCT00004230
- Testing
- captopril, cyclophosphamide, autologous bone marrow transplantation
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Northwestern University
Adult Langerhans Cell Histiocytosis, Childhood Langerhans Cell Histiocytosis
Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Adult Langerhans Cell Histiocytosis, Childhood Langerhans Cell Histiocytosis, Leukemia, Lymphoma
- Trial name
- NCT00008216
- Testing
- Peripheral Blood Stem Cell Transplantation
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Columbia University
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
This phase II trial is studying how well etanercept works in treating young patients with idiopathic pneumonia syndrome after undergoing a donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission
- Trial name
- NCT00309907
- Testing
- etanercept, methylprednisolone
- Where
- 26 sites in United States
- Volunteers
- 39 people
- Sponsor
- Children's Oncology Group
Small Cell Carcinoma of Lung
Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment
The primary treatment option for non-small cell lung cancer (NSCLC) adenocarcinoma (ADC) with activating epidermal growth factor receptor (EGFR) mutation is EGFR tyrosine kinase inhibitor (TKI).
- Trial name
- NCT06830694
- Testing
- Atezolizumab, Etoposide, Carboplatin, Tarlatamab
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Sehhoon Park
Non-small Cell Lung Cancer
Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance
This study aimed to evaluate the efficacy and safety of third-generation EGFR-TKI plus anlotinib as maintenance after chemotherapy plus immunotherapy in advanced NSCLC with small cell transformation after EGFR-TKI resistance.
- Trial name
- NCT06634667
- Testing
- third-generation EGFR-TKI combined with anlotinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hunan Province Tumor Hospital
Small Cell Carcinoma of Lung
A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following EGFR TKI Therapy
The primary treatment option for non-small cell lung cancer (NSCLC) adenocarcinoma with activating epidermal growth factor receptor (EGFR) mutation is EGFR tyrosine kinase inhibitor (TKI).
- Trial name
- NCT07414927
- Testing
- BL0020
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Shanghai Best-Link Bioscience, LLC
Neuroendocrine Carcinoma, Non-small Cell Lung Cancer
Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC
Histology transformation from non-small cell lung cancer (NSCLC) to neuroendocrine carcinomas (NEC), especially from epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma (LADC) to small cell lung cancer (SCLC), is…
- Conditions
- Neuroendocrine Carcinoma, Non-small Cell Lung Cancer, Histology Transformation
- Trial name
- NCT06369181
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Small-cell Lung Cancer
Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment
This investigator-initiated, open-label, prospective Phase II clinical trial, planned to take place across multiple centers in China.
- Trial name
- NCT05957510
- Testing
- Serplulimab, SOC
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Guangdong Association of Clinical Trials